The deadline for stockholders to vote (or change their vote) is 11:59 p.m. EST on Sunday, December 17, 2023 BRISBANE, California, Dec. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (Nasdaq: GTBP) (the “Company”), announced that the two leading independent proxy advisory firms, Institutional Shareholder Services Inc.

股东投票（或更改投票）的截止日期是美国东部时间2023年12月17日星期日下午11:59，加利福尼亚州布里斯班，2023年12月6日（环球通讯社）--GT Biopharma，Inc.（纳斯达克代码：GTBP）（“公司”）宣布，两家领先的独立代理咨询公司，机构股东服务公司。

(“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have recommended GT Biopharma stockholders entitled to vote at the Company’s 2023 Special Meeting of Stockholders (the “Special Meeting”) to vote “FOR” Proposal items number 1 and 2. If approved, Proposal No. 1. will provide the Company’s Board of Directors (the “Board”) with the option to implement a reverse stock split of the Company’s issued and outstanding common stock (the “Reverse Split”), if deemed necessary in the future, to maintain the Company’s listing on the Nasdaq Capital Market (“Nasdaq”).

（“ISS”）和Glass Lewis＆Co.（“Glass Lewis”）建议有权在公司2023年股东特别会议（“特别会议”）上投票的GT Biopharma股东“投票”第1和第2项提案。如获批准，1号提案。将向公司董事会（以下简称“董事会”）提供对公司已发行和流通的普通股实施反向股票分割（以下简称“反向分割”）的选择权，以维持公司在纳斯达克资本市场（以下简称“纳斯达克”）的上市。

“We are pleased that both ISS and Glass Lewis, the leading independent proxy advisory firms, support our Board’s recommendation that stockholders vote “FOR” Proposal No. 1,” said Michael Breen, Executive Chairman and Interim Chief Executive Officer of GT Biopharma, Inc. “Each stockholder’s vote is important, so we strongly encourage each investor to follow the recommendations of ISS and Glass Lewis and vote “FOR” Proposal No.

GT Biopharma执行主席兼临时首席执行官迈克尔·布林（MichaelBreen）表示：“我们很高兴ISS和Glass Lewis这两家领先的独立代理咨询公司都支持我们董事会的建议，即股东投票支持“第一号提案”，每个股东的投票都很重要，因此我们强烈鼓励每个投资者遵循ISS和Glass Lewis的建议，投票支持第号提案。

1 as promptly as possible. Approval of Proposal No. 1 will provide the flexibility that will be essential, should we need to utilize this tool to maintain our Nasdaq listing. Confidence in our ability to maintain our Nasdaq listing will be an important complement to our ongoing efforts to enhance market awareness of the potential of our pipeline to improve the millions of lives and deliver value to our stockholders.” GT Biopharma 2023 Special Meeting Details The Company’s 2023 Special Me.

1尽快。如果我们需要利用这一工具来维持我们在纳斯达克的上市，批准第一号提案将提供必要的灵活性。对我们保持纳斯达克上市能力的信心，将是我们不断努力提高市场对我们改善数百万人生活和为股东创造价值的潜力的认识的重要补充。”GT Biopharma 2023年特别会议详细介绍了该公司的2023年特别Me。